Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

NCT05282953 is registered in ClinicalTrials.gov with Kiora Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05282953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05282953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Lead sponsor
Kiora Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 10, 2022
Completion date
March 24, 2026
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

choroideremia, non-syndromic rod-dominant inherited retinal diseases, retinitis pigmentosa